PUBLISHER: Inkwood Research | PRODUCT CODE: 1348092
PUBLISHER: Inkwood Research | PRODUCT CODE: 1348092
The North America retinal imaging devices market is projected to register a CAGR of 5.47% during the forecast period, 2023-2032. The prevalence of diabetes is on the rise, particularly within the United States, leading to a notable uptick in cases of diabetic retinopathy. Given that diabetic retinopathy stands as a leading cause of vision impairment, it underscores the importance of consistent monitoring and timely intervention. In this context, retinal imaging devices emerge as indispensable instruments for evaluating the progression of this condition.
Canada and the United States are analyzed for the North America retinal imaging devices market growth assessment. As per Diabetes Canada's findings, the escalating incidence of diabetes and the expanding geriatric demographic are collectively exerting a significant impact on the escalating burden of visual impairment. Additionally, it is worth noting that Glaucoma stands as a predominant cause of blindness in Canada, affecting a noteworthy population of over 450,000 individuals, according to data from the Canadian Association of Optometrists.
In accordance with the same source, in the year 2022, the diabetic population in Canada numbered more than 5.7 million individuals (including those with diagnosed type 1 and type 2 diabetes, as well as undiagnosed cases of type 2 diabetes). However, a staggering 11.7 million Canadians were found to have either diabetes or prediabetes, a condition that, if left unattended, can progress into type 2 diabetes. Notably, the annual cost of diabetes treatment to the healthcare system is estimated at $30 billion.
Some of the prominent companies in the North America retinal imaging devices market are: Optos plc, Forus Health Pvt Ltd, Heidelberg Engineering GmbH, Escalon Medical Corp, etc.